PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to onset of 6-month composite confirmed disability progression compared to placebo ...

Neuraly, Inc., a wholly owned subsidiary of D&D Pharmatech, Inc. (KOSDAQ: 347850), announced that the first patient has been dosed in a Phase 2 Investigator-Initiated Trial (IIT) evaluating ...

SAN DIEGO — Results from two phase 3 trials offer mixed findings on the potential of experimental Bruton tyrosine kinase (BTK) inhibitors for primary progressive multiple sclerosis (PPMS). Findings ...

Ocrelizumab (Ocrevus) delayed overall disability progression and worsening of upper limb function in people with primary progressive multiple sclerosis (PPMS) over 144 weeks, the ORATORIO-HAND (O'HAND ...

Investigational vidofludimus calcium missed its primary target in an exploratory phase II study of progressive multiple sclerosis (MS) but showed promising disability-related trends, data from the ...

Genentech's Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1) -FENhance 1 met its primary ...

- Patients on fenebrutinib had low relapse rates with data showing no active brain lesions or disability progression after nearly two years of treatment - - Phase III studies for fenebrutinib in ...

Trial data showed Ocrevus treatment slowed disability progression in PPMS, including patients who were older and had more ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for the investigational medicine ocrelizumab (OCREVUSTM ...

Iron dysregulation contributes to MS progression through oxidative stress, ferroptosis, and immune activation, affecting neuronal and immune cell function. Both iron overload and deficiency exacerbate ...

MENLO PARK, Calif.--(BUSINESS WIRE)--Octave Bioscience, Inc., a commercial-stage precision care company pioneering biomarker-driven solutions for multiple sclerosis (MS) and other neurodegenerative ...